Adverum Biotechnologies Holds Annual Meeting with Key Votes

The latest announcement is out from Adverum Biotechnologies ( (ADVM) ).

On June 17, 2025, Adverum Biotechnologies held its Annual Meeting, where stockholders voted on several key proposals. The election of Class II directors, ratification of Ernst & Young LLP as the independent accounting firm, and approval of executive compensation were among the decisions made. Additionally, stockholders approved amendments to the 2024 Equity Incentive Award Plan and the reduction of exercise prices for certain stock options, reflecting strategic adjustments to enhance shareholder value.

The most recent analyst rating on (ADVM) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Adverum Biotechnologies stock, see the ADVM Stock Forecast page.

Spark’s Take on ADVM Stock

According to Spark, TipRanks’ AI Analyst, ADVM is a Underperform.

Adverum Biotechnologies’ overall score is heavily weighed down by its poor financial performance, highlighted by persistent losses and cash flow difficulties. Technical analysis indicates weak market momentum, while valuation metrics are unattractive due to negative earnings. The company’s financial challenges are further compounded by recent negative corporate events, although this was not a weighted factor in the score.

To see Spark’s full report on ADVM stock, click here.

More about Adverum Biotechnologies

Adverum Biotechnologies operates in the biotechnology industry, focusing on developing gene therapy solutions. The company is primarily engaged in creating innovative treatments for ocular and rare diseases, aiming to address unmet medical needs in these areas.

Average Trading Volume: 335,415

Technical Sentiment Signal: Sell

Current Market Cap: $51.6M

For a thorough assessment of ADVM stock, go to TipRanks’ Stock Analysis page.